Seeking Alpha

Cowen says Alkermes (ALKS +2.4%) should be bought at current levels , citing the value of its...

Cowen says Alkermes (ALKS +2.4%) should be bought at current levels , citing the value of its diabetes drug Bydureon and its potential profitability for the company. The firm believes the royalty stream could be worth more than $1B, or $8 per share, which would drive significantly higher valuations.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs